Québec has become the first province to include financial coverage for any BTK inhibitor on its provincial drug formulary.  This is excellent news for WMers in Québec.  And we hope this will set an example for other provinces (although they are quite independent from one another in making such decisions).

The announced coverage is for BeiGene’s Brukinsa, or zanubrutinib.  BeiGene’s news release can be found here.